Summary
GSK CEO Dame Emma Walmsley stated that the U.S. is the best place for business investment and announced a $30 billion investment there by 2030. She noted that other pharmaceutical companies are turning away from the UK due to challenges with NHS drug budgets and U.S. pressure to produce locally. However, a new UK-U.S. deal keeps tariffs on British pharmaceuticals at zero, encouraging investment.
Key Facts
- GSK plans to invest $30 billion in the U.S. by 2030.
- Dame Emma Walmsley noted the U.S. as a leading market for drug and vaccine launches.
- UK pharmaceutical projects face challenges from NHS budget constraints and U.S. production pressures.
- A UK-U.S. deal ensures zero tariffs on UK-made drugs, with the UK paying more for NHS medicines.
- Other companies like Merck and AstraZeneca are pausing UK projects in favor of U.S. investments.
- The agreement aims to boost innovation, like GSK's new asthma drug awaiting NHS approval.
- Dame Emma highlighted the impact of social demographics and diet on UK health outcomes.
- Differences between the UK's NHS and U.S. private healthcare were noted by Dame Emma based on her personal experiences.
